Clinical Trials

Verified stories whose regulatory record supports clinical-trial access. Eligibility and enrollment are never guaranteed.

Filter clinical trials

Results

162 verified trial-access stories match your filters.

Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.

Trial Watch: Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial

InvestigationalRegistered later-phase trial

Cancer type: Cervical Cancer
Trial identifier: NCT05237947
Trial phase: Phase 4

View trial details

Study design: Not specified in this summary
Population: Participants ages 18 Years to 30 Years with Human Papillomavirus-Related Cervical Carcinoma who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05237947 (opens in a new tab) (Clinical-trial registry) NCT05237947 Primary source NCT05237947
ClinicalTrials.gov — NCT05237947. NCT05237947.

Eligibility varies — review trial criteria.

Trial Watch: Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

InvestigationalRegistered later-phase trial

Cancer type: Cervical Cancer
Trial identifier: NCT07061977
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IIIA Cervical Cancer FIGO 2018 who meet the study-specific registry eligibility criteria; sex eligibility: female.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07061977 (opens in a new tab) (Clinical-trial registry) NCT07061977 Primary source NCT07061977
ClinicalTrials.gov — NCT07061977. NCT07061977.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

InvestigationalRegistered later-phase trial

Cancer type: Multiple Myeloma
Trial identifier: NCT07393282
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with High Risk Smoldering Multiple Myeloma (HR-SMM) who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07393282 (opens in a new tab) (Clinical-trial registry) NCT07393282 Primary source NCT07393282
ClinicalTrials.gov — NCT07393282. NCT07393282.

Eligibility varies — review trial criteria.

Trial Watch: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

InvestigationalRegistered later-phase trial

Cancer type: Leukemia, Lymphoma
Trial identifier: NCT02112916
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants ages 1 Year to 30 Years with Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT02112916 (opens in a new tab) (Clinical-trial registry) NCT02112916 Primary source NCT02112916
ClinicalTrials.gov — NCT02112916. NCT02112916.

Eligibility varies — review trial criteria.

Trial Watch: A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

InvestigationalRegistered later-phase trial

Cancer type: Lymphoma
Trial identifier: NCT05139017
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with DLBCL, Diffuse Large B-Cell Lymphoma who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-22

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-22

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05139017 (opens in a new tab) (Clinical-trial registry) NCT05139017 Primary source NCT05139017
ClinicalTrials.gov — NCT05139017. NCT05139017.

Eligibility varies — review trial criteria.

Trial Watch: A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations

InvestigationalRegistered later-phase trial

Cancer type: Lung Cancer
Trial identifier: NCT05048797
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants ages 18 Years to 123 Years with Locally Advanced or Metastatic Non-Small Cell Lung Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05048797 (opens in a new tab) (Clinical-trial registry) NCT05048797 Primary source NCT05048797
ClinicalTrials.gov — NCT05048797. NCT05048797.

Eligibility varies — review trial criteria.

Trial Watch: Self-administered Subcutaneous Daratumumab in Patients With Multiple Myeloma

InvestigationalRegistered later-phase trial

Cancer type: Multiple Myeloma
Trial identifier: NCT07191379
Trial phase: Phase 4

View trial details

Study design: Not specified in this summary
Population: Participants with Multiple Myeloma in Relapse who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT07191379 (opens in a new tab) (Clinical-trial registry) NCT07191379 Primary source NCT07191379
ClinicalTrials.gov — NCT07191379. NCT07191379.

Eligibility varies — review trial criteria.

Trial Watch: Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype

InvestigationalRegistered later-phase trial

Cancer type: Lymphoma
Trial identifier: NCT06947967
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants ages 18 Years to 80 Years with Lymphoma, T-Cell, Peripheral who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06947967 (opens in a new tab) (Clinical-trial registry) NCT06947967 Primary source NCT06947967
ClinicalTrials.gov — NCT06947967. NCT06947967.

Eligibility varies — review trial criteria.

Trial Watch: Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

InvestigationalRegistered later-phase trial

Cancer type: Bladder Cancer
Trial identifier: NCT06510374
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants age 18 Years and older with Intermediate Risk Non-Muscle Invasive Bladder Cancer who meet the study-specific registry eligibility criteria.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT06510374 (opens in a new tab) (Clinical-trial registry) NCT06510374 Primary source NCT06510374
ClinicalTrials.gov — NCT06510374. NCT06510374.

Eligibility varies — review trial criteria.

Trial Watch: An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

InvestigationalRegistered later-phase trial

Cancer type: Prostate Cancer
Trial identifier: NCT05939414
Trial phase: Phase 3

View trial details

Study design: Not specified in this summary
Population: Participants ages 18 Years to 100 Years with Oligometastatic Prostate Cancer (OMPC) who meet the study-specific registry eligibility criteria; sex eligibility: male.
Last reviewed: 2026-10-21

Regulatory status by jurisdiction

Country or region not specified

Status: Investigational
Last verified: 2026-10-21

Cancer-type scope for this record is not yet recorded.

Primary evidence supporting this story

ClinicalTrials.gov — NCT05939414 (opens in a new tab) (Clinical-trial registry) NCT05939414 Primary source NCT05939414
ClinicalTrials.gov — NCT05939414. NCT05939414.

Eligibility varies — review trial criteria.

CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.